Sasi P, Makubi A, Sangeda R, Ngaeje M, Mmbando B, Soka J
Commun Med (Lond). 2024; 4(1):160.
PMID: 39122788
PMC: 11315961.
DOI: 10.1038/s43856-024-00552-5.
Smaldone A, Manwani D, Aygun B, Appiah-Kubi A, Smith-Whitley K, Green N
Pediatr Blood Cancer. 2024; 71(9):e31170.
PMID: 38975794
PMC: 11268999.
DOI: 10.1002/pbc.31170.
Madkhali M, Abusageah F, Hakami F, Zogel B, Hakami K, Alfaifi S
Medicina (Kaunas). 2024; 60(1).
PMID: 38256385
PMC: 10819561.
DOI: 10.3390/medicina60010124.
King K, Cai S, Barrera L, Reddy P, Heneghan M, Badawy S
Pediatr Blood Cancer. 2023; :e30440.
PMID: 37243925
PMC: 10679470.
DOI: 10.1002/pbc.30440.
Janson I, Bloom E, Hampton K, Meier E, Rampersad A, Kronenberger W
Patient Prefer Adherence. 2022; 16:3229-3239.
PMID: 36531301
PMC: 9749495.
DOI: 10.2147/PPA.S387227.
Penicillin V prophylaxis uptake among children living with sickle cell disease in a specialist sickle cell clinic in Ghana: A cross-sectional study.
Odoom S, Newton S, Nakua E, Boahen K, Nguah S, Ansong D
Health Sci Rep. 2022; 5(6):e953.
PMID: 36439045
PMC: 9686354.
DOI: 10.1002/hsr2.953.
Bloodstream Infections in Children With Sickle Cell Disease: 2010-2019.
Yee M, Lai K, Bakshi N, Grossman J, Jaggi P, Mallis A
Pediatrics. 2021; 149(1).
PMID: 34913059
PMC: 8959248.
DOI: 10.1542/peds.2021-051892.
Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Efficacy and Implementation Study.
Hankins J, Shah N, DiMartino L, Brambilla D, Fernandez M, Gibson R
JMIR Res Protoc. 2020; 9(7):e16319.
PMID: 32442144
PMC: 7388044.
DOI: 10.2196/16319.
A Quality Initiative to Decrease Time to Antibiotics in Children with Sickle Cell Disease and Fever.
McKinney C, Caruso-Brown A, Montgomery K, Gillespie A, Coughlin R, Law D
Pediatr Qual Saf. 2020; 5(1):e245.
PMID: 32190792
PMC: 7056294.
DOI: 10.1097/pq9.0000000000000245.
Sickle-Cell Disease Co-Management, Health Care Utilization, and Hydroxyurea Use.
Crego N, Douglas C, Bonnabeau E, Earls M, Eason K, Merwin E
J Am Board Fam Med. 2020; 33(1):91-105.
PMID: 31907250
PMC: 7942752.
DOI: 10.3122/jabfm.2020.01.190143.
Comparative Effectiveness of a Web-Based Patient Decision Aid for Therapeutic Options for Sickle Cell Disease: Randomized Controlled Trial.
Krishnamurti L, Ross D, Sinha C, Leong T, Bakshi N, Mittal N
J Med Internet Res. 2019; 21(12):e14462.
PMID: 31799940
PMC: 6934048.
DOI: 10.2196/14462.
Hydroxyurea Initiation Among Children With Sickle Cell Anemia.
Reeves S, Jary H, Gondhi J, Raphael J, Lisabeth L, Dombkowski K
Clin Pediatr (Phila). 2019; 58(13):1394-1400.
PMID: 31113236
PMC: 7060659.
DOI: 10.1177/0009922819850476.
Paediatric immunisation and chemoprophylaxis in a Ugandan sickle cell disease clinic.
Chen C, Bakeera-Kitaka S, Mupere E, Kasirye P, Munube D, Idro R
J Paediatr Child Health. 2018; 55(7):795-801.
PMID: 30411430
PMC: 6509021.
DOI: 10.1111/jpc.14291.
Association between Participants' Characteristics, Patient-Reported Outcomes, and Clinical Outcomes in Youth with Sickle Cell Disease.
Badawy S, Barrera L, Cai S, Thompson A
Biomed Res Int. 2018; 2018:8296139.
PMID: 30105252
PMC: 6076920.
DOI: 10.1155/2018/8296139.
Antibiotic Prophylaxis for Children With Sickle Cell Anemia.
Reeves S, Tribble A, Madden B, Freed G, Dombkowski K
Pediatrics. 2018; 141(3).
PMID: 29437860
PMC: 7252515.
DOI: 10.1542/peds.2017-2182.
Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults.
Badawy S, Thompson A, Lai J, Penedo F, Rychlik K, Liem R
Health Qual Life Outcomes. 2017; 15(1):136.
PMID: 28679417
PMC: 5498866.
DOI: 10.1186/s12955-017-0713-x.
Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use.
Green N, Manwani D, Qureshi M, Ireland K, Sinha A, Smaldone A
Pediatr Blood Cancer. 2016; 63(12):2146-2153.
PMID: 27573582
PMC: 5072999.
DOI: 10.1002/pbc.26161.
A validated measure of adherence to antibiotic prophylaxis in children with sickle cell disease.
Duncan N, Kronenberger W, Hampton K, Bloom E, Rampersad A, Roberson C
Patient Prefer Adherence. 2016; 10:983-92.
PMID: 27354768
PMC: 4908942.
DOI: 10.2147/PPA.S103874.
Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease.
Smaldone A, Findley S, Bakken S, Matiz L, Rosenthal S, Jia H
Contemp Clin Trials. 2016; 49:134-42.
PMID: 27327779
PMC: 5024731.
DOI: 10.1016/j.cct.2016.06.004.
Adherence to hydroxyurea medication by children with sickle cell disease (SCD) using an electronic device: a feasibility study.
Inoue S, Kodjebacheva G, Scherrer T, Rice G, Grigorian M, Blankenship J
Int J Hematol. 2016; 104(2):200-7.
PMID: 27225236
DOI: 10.1007/s12185-016-2027-x.